Reciever Operating Chacteristic curves comparing CA19-9 at its clinical cut-off of 37 U/ml and optimal cut-off of 55.1 U/ml in treatment naïve group.

<p>ROC curve analyses for assessing the ability of CA19-9 to differentiate PC form HC (panel A) and PC from CP (panel B) at its clinical cut off (37 U/ml) (red line), and optimal cut-off (55.1 U/ml) (blue line). At a cutoff of 37 U/mL, CA19-9 differentiated treatment naïve PC patients from healthy controls with sensitivity, specificity of 83% and 67%, while sensitivity and specificity of 79% and 92% was observed at 55.1 U/ml. In case of PC vs CP patients, sensitivity and specificity of 61% and 83% were observed at clinical cut-off while at optimal cut-off 62.2 U/ml sensitivity increased to 79% with specificity of 78%.